Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2019-07-25 Earnings Release
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a press release from Onxeo S.A. announcing its financial results for the first half of 2019. It includes key highlights, business updates, and a summary financial table (income statement). While it contains financial data, it is structured as a corporate announcement (press release) rather than a full statutory interim report. According to the classification rules, this fits the definition of an Earnings Release (ER) as it provides the initial announcement of periodical financial results with key highlights. H1 2019
2019-07-25 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its main subject is the "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ" (Semi-annual review of the liquidity contract) as of June 30, 2019. This document reports on the status and transactions related to a liquidity agreement managed by Kepler Cheuvreux, which is a financing/market stabilization activity. While it relates to capital management, it is not a formal capital raising (CAP) or a share repurchase announcement (POS). It is a periodic disclosure regarding a specific financial arrangement. Since it is a periodic report on a specific financial mechanism, and not a general earnings release (ER) or a comprehensive interim report (IR), it fits best under Capital/Financing Update (CAP) as it details the activity of a liquidity contract, which is a form of capital market arrangement. However, given the specific nature of reporting on a liquidity contract balance, it is a specialized financial disclosure. It is not a standard earnings release, nor a full interim report. It is a specific update on a financing/market support mechanism. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate category for reporting on the status of a liquidity contract, as this contract is a financing tool used to support the stock price/marketability of capital.
2019-07-03 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Capital/Financing Update Classification · 1% confidence The document is a press release dated July 3, 2019, detailing the status of a liquidity contract with Kepler Cheuvreux as of June 30, 2019. It reports on the number of shares and cash held in the liquidity account, and summarizes the trading activity (buy/sale) during the first half of 2019. This type of announcement, which reports on specific financial arrangements or transactions outside of standard periodic financial reports (like 10-K or IR), often falls under general regulatory announcements or specific transaction reporting. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it specifically details the status of a market-making/liquidity agreement, it is best classified as a general Regulatory Filing (RNS) as it is a required disclosure to the market regarding market operations, or potentially a Capital/Financing Update (CAP) if the liquidity contract is viewed as a financing tool, but RNS is the broader, safer category for non-standard disclosures like this. Given the context of reporting on market activity and compliance with AMF decisions, RNS is the most appropriate general regulatory disclosure category.
2019-07-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated July 1, 2019, announcing that Kepler Cheuvreux has initiated coverage on the stock of Onxeo S.A. It explicitly states that Kepler Cheuvreux will now follow the stock and that the financial analysis published on June 28, 2019, is accessible on their website. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER). It is an announcement about external research coverage being initiated. This type of announcement, which informs the market about the availability of new research/analysis, fits best under the general category of regulatory announcements or investor relations updates. Since there is no specific category for 'Analyst Coverage Initiation,' and it is a formal announcement regarding company information dissemination, it falls under the broad 'Regulatory Filings' (RNS) as a general regulatory/market information update, or potentially 'Report Publication Announcement' (RPA) if interpreted as announcing the publication of the Kepler Cheuvreux report. Given the context of informing the market about external research coverage, RNS is a suitable fallback for non-standard announcements. However, since it specifically mentions the publication of an analysis and directs readers to where it can be found, RPA is also plausible. I will lean towards RNS as the most general fit for market-moving news that isn't a core financial filing or earnings report.
2019-07-01 French
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release dated June 20, 2019, announcing a corporate development: the advancement of a new drug candidate (OX401) into preclinical proof-of-concept studies. It details scientific progress, intellectual property, and future milestones (results expected Q4 2019). This type of announcement, focusing on R&D pipeline updates, product news, and corporate strategy announcements outside of mandatory periodic financial reporting (like 10-K or IR), is typically classified as an Investor Presentation (IP) if it were a deck, or more generally, a corporate announcement. Since it is a detailed press release announcing pipeline progress and strategy updates, it aligns best with the 'Investor Presentation' (IP) category, which often encompasses detailed strategic updates shared with investors, even if not strictly a slide deck. It is not a formal financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the detailed scientific and strategic nature aimed at investors, IP is the most fitting specific category, although RNS (Regulatory Filings) could also apply if IP was reserved strictly for slide decks. However, IP is defined as 'Detailed presentation for investors focusing on financials, strategy, and market position,' which this text strongly reflects.
2019-06-20 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated June 20, 2019, announcing a scientific and pipeline update regarding a new drug candidate, OX401, entering preclinical development. It details the mechanism of action, patent filing, and expected results timeline (early Q4 2019). This type of announcement, focusing on R&D progress, pipeline expansion, and upcoming data milestones, is characteristic of communications from clinical-stage biotechnology companies to the investment community. It is not a formal regulatory filing like a 10-K, a quarterly report (IR), an earnings release (ER), or a proxy statement (DEF 14A). Since it is a specific announcement detailing company progress and strategy aimed at investors, the most appropriate classification among the provided options is Investor Presentation (IP), as these often include detailed scientific updates, although it is structured as a press release. However, given the content is a detailed update on R&D pipeline and strategy, it aligns closely with the intent of an Investor Presentation or a detailed corporate update. Since it is not explicitly an 'Earnings Release' (ER) or a formal 'Interim Report' (IR), and it is a detailed update, 'IP' (Investor Presentation) is the best fit for conveying strategic and scientific progress to investors, even if the format is a press release. It is not a Report Publication Announcement (RPA) because it is the primary source of the information, not just an announcement that a report is available.
2019-06-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.